AcelRx begins Phase III IAP312 study of Zalviso to manage acute post-operative pain

US-based specialist pharmaceutical company AcelRx has begun its Phase III IAP312 study of Zalviso to treat moderate-to-severe acute post-operative pain in adult patients in a hospital setting.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news